Clinical Trial Continuity

Clinical trial continuity is the source’s move from episodic regulatory submissions toward ongoing evidence review. In Supercharging a New FDA: Marty Makary on Science, Power & Patients, Marty Makary supports Bayesian statistics, continuous trials, and endpoints in the cloud so FDA reviewers can monitor safety and efficacy signals in real time.

The concept does not eliminate trial rigor. It changes the operating model: instead of waiting for large applications after each development stage, reviewers could watch the data stream, detect emerging issues earlier, and reduce duplicated paperwork around otherwise legible signals.

Key Claims

• Continuous evidence review can make regulatory work less episodic and less paperwork-bound.
• Bayesian methods let prior and emerging evidence be used more flexibly than a fixed-only trial structure.
• Cloud endpoints make the regulatory problem partly one of data access, validation, permissions, and monitoring discipline.
• The approach needs Post-Market Drug Surveillance and Clinical Development Capability to avoid confusing early signal visibility with final proof.

Connections

• FDA Review Modernization - umbrella reform frame.
• FDA and Marty Makary - agency and source speaker.
• Clinical Development Capability - company-side trial execution capability.
• Post-Market Drug Surveillance - safety-monitoring counterpart.